Fig. 2

Immunostaining of wholemounts and counting of RGCs after exposure to ROCKis. a Representative images of wholemount retinal explants in culture at DEV 0 and control solvent DEV 4 or treated DEV 4 groups (500 µM Y-27632, 50 µM Y-33075, and 100 µM H-1152) immunolabeled with Brn3a at 20 × magnification (scale bar = 150 µm). b Quantification of Brn3a⁺ RGCs (n = 9–24 per group, ****p < 0.0001) from wholemount retinal explants. Unpaired t tests or Mann–Whitney tests were performed between the control and each treated group at DEV 4. Error bars indicate the standard error of the mean